Compositions Comprising 5-Cholesten-3, 25-Diol, 3-Sulfate (25HC3S) or Pharmaceutically Acceptable Salt Thereof And at Least One Cyclic Oligosaccharide

1 - 24 . (canceled)

25 . A composition comprising:

5-cholesten-3,25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof, wherein the 25HC3S or pharmaceutically acceptable salt thereof is present in the composition at a concentration ranging from 0.01% (w/w) to 3% (w/w); and

an aqueous vehicle comprising at least one buffer and at least one cyclic oligosaccharide comprising at least one of hydroxypropyl β-cyclodextrin and sulfobutyl ether β-cyclodextrin.

26 . The composition of claim 25 , wherein the 25HC3S or pharmaceutically acceptable salt thereof comprises a pharmaceutically acceptable salt of 25HC3S.

27 . The composition of claim 25 , wherein the 25HC3S or pharmaceutically acceptable salt thereof comprises sodium salt of 25HC3S.

28 . The composition of claim 25 , wherein the 25HC3S or pharmaceutically acceptable salt thereof is present in the composition in an amount ranging from 0.01% (w/w) to 1% (w/w).

29 . The composition of claim 25 , wherein the at least one cyclic oligosaccharide is present in the composition at a concentration ranging from 0.1% (w/w) to 40% (w/w).

30 . The composition of claim 25 , wherein the at least one cyclic oligosaccharide is present in the composition at a concentration ranging from 4% (w/w) to 30% (w/w).

31 . The composition of claim 25 , wherein the at least one cyclic oligosaccharide is present in the composition at a concentration ranging from 0.1% (w/w) to 1% (w/w).

32 . The composition of claim 25 , wherein the composition has an osmolality ranging from 270 mmol/kg to 340 mmol/kg.

33 . The composition of claim 25 , wherein the composition has an osmolality ranging from 270 mmol/kg to 616 mmol/kg.

34 . The composition of claim 25 , wherein the at least one buffer is phosphate buffer.

35 . The composition of claim 25 , wherein the at least one buffer is present in the composition at a concentration ranging from 0.1 mM to 50 mM.

36 . The composition of claim 25 , wherein:

the 25HC3S or pharmaceutically acceptable salt thereof comprises a pharmaceutically acceptable salt of 25HC3S;

the at least one cyclic oligosaccharide is present in the composition at a concentration ranging from 1% (w/w) to 40% (w/w); and

a volume of the composition ranges from 0.5 mL to 5 mL.

37 . The composition of claim 36 , wherein the 25HC3S or pharmaceutically acceptable salt thereof comprises sodium salt of 25HC3S.

38 . The composition of claim 25 , wherein:

the 25HC3S or pharmaceutically acceptable salt thereof is present in the composition in an amount ranging from 0.01% (w/w) to 1% (w/w);

the at least one cyclic oligosaccharide is present in the composition at a concentration ranging from 0.1% (w/w) to 4% (w/w); and

a volume of the composition ranges from 50 mL to 1000 mL.

39 . The composition of claim 38 , wherein the 25HC3S or pharmaceutically acceptable salt thereof comprises sodium salt of 25HC3S.

40 . The composition of claim 25 , wherein:

the 25HC3S or pharmaceutically acceptable salt thereof is present in the composition at a concentration of about 30 mg/mL;

the at least one cyclic oligosaccharide is present in the composition at a concentration of about 240 mg/mL; and

the at least one buffer present is in the composition at a concentration of about 50 mM.

41 . A method of treating alcoholic hepatitis in a subject in need thereof, comprising administering an effective amount of a composition comprising:

5-cholesten-3,25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof; and

at least one cyclic oligosaccharide.

42 . The method of claim 41 , wherein the composition is administered intravenously.

43 . The method of claim 41 , wherein the composition is aqueous.

44 . The method of claim 41 , wherein the composition further comprises at least one buffer.